Development of a radiolabeled irreversible peptide ligand for PET imaging of vascular endothelial growth factor

Academic Article

Abstract

  • Imaging agents based on peptide probes have desirable pharmacokinetic properties provided that they have high affinities for their target in vivo. An approach to improve a peptide ligand's affinity for its target is to make this interaction covalent and irreversible. For this purpose, we evaluated a 64Cu-labeled affinity peptide tag, 64Cu- L19K-(5-fluoro-2,4-dinitrobenzene) (64Cu-L19K-FDNB), which binds covalently and irreversibly to vascular endothelial growth factor (VEGF) as a PET imaging agent. We compared the in vivo properties of 64Cu-L19K- FDNB in VEGF-expressing tumor xenografts with its noncovalent binding analogs, 64Cu-L19K-(2,4-dinitrophenyl) (64Cu-L19K-DNP) and 64Cu-L19K. Methods: The L19K peptide (GGNECDIARMWEWECFERK-CONH 2) was constructed with 1,4,7-triazacyclononane-1,4,7-triacetic acid at the N terminus for radiolabeling with 64Cu with a polyethylene glycol spacer between peptide and chelate. 1,5-difluoro-2,4-dinitrobenzene was conjugated at the C-terminal lysine for cross-linking to VEGF, resulting in L19K-FDNB. 64Cu-L19K-FDNB was assayed for covalent binding to VEGF in vitro. As a control, L19K was conjugated to 1-fluoro-2,4-dinitrobenzene, resulting in L19K-DNP. PET imaging and biodistribution studies of 64Cu-L19K-FDNB, 64Cu-L19K-DNP, and the native 64Cu-L19K were compared in HCT-116 xenografts. Blocking studies of 64Cu-L19K-FDNB was performed with a coinjection of excess unlabeled L19K-FDNB. Results: In vitro binding studies confirmed the covalent and irreversible binding of 64Cu-L19K-FDNB to VEGF, whereas 64Cu-L19K-DNP and 64Cu-L19K did not bind covalently. PET imaging showed higher tumor uptake with 64Cu-L19K-FDNB than with 64Cu-L19K-DNP and 64Cu-L19K, with mean standardized uptake values of 0.62 ± 0.05, 0.18 ± 0.06, and 0.34 ± 0.14, respectively, at 24 h after injection (P < 0.05), and 0.53 ± 0.05, 0.32 ± 0.14, and 0.30 ± 0.09, respectively, at 48 h after injection (P < 0.05). Blocking studies with 64Cu-L19K-FDNB in the presence of excess unlabeled peptide showed a 53% reduction in tumor uptake at 48 h after injection. Conclusion: In this proof-of-concept study, the use of a covalent binding peptide ligand against VEGF improves tracer accumulation at the tumor site in vivo, compared with its noncovalent binding peptide analogs. This technique is a promising tool to enhance the potency of peptide probes as imaging agents. Copyright © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
  • Digital Object Identifier (doi)

    Author List

  • Marquez BV; Ikotun OF; Parry JJ; Rogers BE; Meares CF; Lapi SE
  • Start Page

  • 1029
  • End Page

  • 1034
  • Volume

  • 55
  • Issue

  • 6